Loading clinical trials...
Loading clinical trials...
Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
BC Cancer - Vancouver
Vancouver, British Columbia, Canada
Start Date
June 1, 2025
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2027
Last Updated
April 22, 2025
36
ESTIMATED participants
DOTATATE-PET scan
DIAGNOSTIC_TEST
Lead Sponsor
British Columbia Cancer Agency
NCT05940493
NCT02523014
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06377371